Sales potential for Lundbeck's new drug upgraded  

The pharmaceutical company's new drug Bifeprunox for the treatment of Schizophrenia has greater sales potential than previously estimated

According to Børsen, pharmaceutical company Lundbeck's new drug Bifeprunox for the treatment of Schizophrenia has much greater sales potential than previously estimated. Bifeprunox was originally created by the Belgian chemical and pharmaceutical concern Solvay. Together with its new cooperation partner Wyeth, Solvay has now reassessed the drug's revenue potential.


For the US market, annual revenue potential is estimated to be around DKK 6 billion (USD 960 million), while revenues in Europe are estimated to reach almost DKK 2 billion (USD 320 million). Lundbeck has the sales rights worldwide apart from the US, Mexico and Japan, while Solvay will receive licence earnings from sales. Lundbeck plans to launch Bifeprunox in 2007.


Headquartered in Copenhagen, Lundbeck is in engaged in R&D, production, marketing and sales of drugs for the treatment of psychiatric and neurological disorders. The company, which employs over 5,000 people, generated revenues of DKK 9.9 billion (USD 1.6 billion) in 2003. The news is reported by financial newspaper Børsen online.


Link > Lundbeck 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×